Alto Neuroscience IncANRO
Price$25.53

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$84.2MTTM through 30 Jun 2026
Free Cash Flow -$68.8MTTM through 30 Jun 2026

Margins

Current

Returns

-41.8%ROE
-34.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio14.85x
Net Debt-$177Mnet cash position
Cash & Equivalents$243.7M

Quality Metrics

Altman Z-Score19.35
Piotroski F-Score2 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS-$2.32TTM
'23'24'25
FY2025: $-2.19

Dividend

No dividend

Capital Allocation

R&D Spend$64.9M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.